Valerie Harvey, MD, MPH, FAAD, discusses pigmentary disorders like melasma and hyperpigmentation, highlighting their disproportionate impact on women, particularly those with skin of color.
VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.
Immunotherapy agent nemvaleukin alfa was granted an FDA fast track designation for the treatment of patient’s mucosal melanoma for previously undergone treatment with an anti-PD-L1 therapy.
Founder Dina El-Sherif, MBA, gave an in-depth overview of the at-home facial rejuvenation device and its 3-step process at AAD 2024.
Many patients with severe AD are unaware of newer, more effective treatments.
Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.
“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.
In one-third of cases of psoriasis, disease onset occurs in the first or second decade of life, although it may not be diagnosed until the patient has reached adulthood.
Diego Ruiz Dasilva, MD, FAAD, reviews the unmet needs and barriers in the treatment landscape of atopic dermatitis.
It effects most teenagers and can lead to mental distress. Here are 5 important facts about acne vulgaris in adolescents.
Sexual and gender minority patients with chronic inflammatory skin diseases may be disproportionately influenced by cost and noncost obstacles to health care.
Ronda Farah, MD, and her colleagues reviewed how dermatology providers play an important role in transgender aesthetic care.
Eric Simpson, MD, MCR, FAAD, lead author of a recently-published article highlighting roflumilast cream 0.15%, joined us for a Q+A interview.
Researchers sought to expand knowledge of the role of cannabis and its molecular mechanisms in anticancer effects.
Christophe Bourdon, CEO, discusses LEO Pharma's groundbreaking presentations at EADV, delgocitinib's US pending approval, and the company's commitment to addressing chronic hand eczema.
Ahmad Amin, MD, FAAD, reviews biologic selection in patients with psoriatic disease.
Learn more about the OX40-OX40L pathway and 2 drugs heading toward phase 3 trials.
Explore how BCs are supported through complex drug approvals and ensuring patients have access to prescribed medications.
Jane Bellet, MD, will present 2 sessions full of pearls to ensure tiny fingers and toes are cared for in a timely, heartfelt, and effective treatment regimen.
Daphne Chan, PhD, MHEcon, discusses the Pathways program, a partnership between the AAD, Janssen, and Kenvue to mentor young, aspiring dermatology providers.
A study found that 65.8% of US adults distrust their health care system’s use of AI, highlighting a need for better communication on AI tools.
“It's so exciting to see all these incredible female talents behind me. I want to give back and I want to help them climb on my shoulders and go higher,” Haws said.
Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.
Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.
An expert in dermatology shares his thoughts on the educational and unmet needs in the identification and management of patients with GPP.
In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical clinical presentation.